Sapience Therapeutics, Inc.

8 articles with Sapience Therapeutics, Inc.

• Sapience Therapeutics Appoints J. Andrew Sanford to Its Board of Directors

  12/1/2020

  Sapience Therapeutics, Inc., a clinical stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it has appointed J. Andrew Sanford to its Board of Directors.

• Sapience Therapeutics Renews Drug Discovery Pact with the University of Bath

  11/19/2020

  Sapience Therapeutics , Inc., a clinical stage biotechnology company focused on discovering and developing peptide therapeutics to address difficult to treat oncology indications, announced today that it has renewed its research collaboration agreement with the University of Bath for the discovery of new therapeutic agents. "The continuation of this drug discovery partnership with Dr. Jody Mason and the University of Bath speaks to the succ

• Sapience Therapeutics Completes $14 million Preferred Stock Financing

  11/17/2020

  Sapience Therapeutics, Inc., a clinical stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it has raised $14 million in its preferred stock financing. Sapience issued shares of its convertible preferred stock in this financing. The net proceeds from the preferred stock f

• Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute

  8/19/2020

  Sapience Therapeutics, Inc., announced today that it was awarded a Small Business Innovative Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to investigate ST101 activity against breast cancer.

• Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors

  8/12/2020

  Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat oncology indications, today announced dose administration for the first patient in a Phase 1/2, open-label, dose escalation and expansion study of single agent ST101,

• Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications

  6/4/2020

  Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat oncology indications, announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug application for ST101, a peptide therapy being evaluated for the treatment of adults with unresectable and metastatic solid tumors.

• Bioinc@NYMC Welcomes Biotechnology Company Sapience Therapeutics

  8/3/2016

• New York Startup Sapience Therapeutics Nabs $22.5 Million Series A Financing

  7/12/2016